Agomab Therapeutics N.V.

https://www.agomab.com

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure, and restore organ function. By combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in fibrotic diseases. Agomab’s pipeline of growth factor targeting antibodies and small molecule compounds includes its lead candidate AGMB-129, a gastrointestinal tract restricted ALK5 inhibitor for which it has recently started a Phase 2a clinical trial in Fibrostenosing Crohn’s Disease and received U.S. FDA Fast Track Designation. The second TGFß targeting pipeline candidate, AGMB-447, is a Phase-1-ready lung-restricted ALK5-inhibitor for treatment of idiopathic pulmonary fibrosis. AGMB-101 is an HGF-mimetic cMET receptor agonist in IND-enabling development for the treatment of fibrotic disorders. *

	Start	2017-01-01 established
	Group	Agomab Therapeutics (Group)
	Industry	growth factor-mimetic agonistic monoclonal antibody (agomAb)
	Industry 2	SIMPLE Antibody™ discovery platform
	Person	Knotnerus, Tim (AgomAb Therapeutics 201904c– CEO before AM-Pharma + Aescap Venture)
	Person 2	Hassan, Tolga (AgomAb Therapeutics 202103– CFO before F-Star + Johnson Matthey)

	Region	Gent (Ghent)
	Country	Belgium
	Street	2/104 Pieter Van Reysschootlaan
	City	9051 Sint-Denijs-Westrem (Gent)
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Agomab Therapeutics N.V.. (10/10/23). "Press Release: Agomab Raises $100 Million Series C to Advance Fibrosis-focused Pipeline". Ghent.

		Record changed: 2024-02-12